


# Tissue healing makes the difference



Early strength

Long-term safety and comfort


Optimised fibrosis



#### TISSUE HEALING MAKES THE DIFFERENCE

**4DMESH** is a hydrophilic partially resorbable implant, designed for the treatment of inguinal hernias by open and laparoscopic approach.

#### PRODUCT'S KEY POINTS



Time



## Early strength and long-term comfort

The 4DMesh concept lies in the 75% PLLA resorption which initially provides maximal strength to prevent early recurrences and in the long-term, leaves small amount of material thus persistant tensile strength for patient comfort<sup>(2)</sup>.

# **Optimised** fibrosis<sup>(1)</sup>

PLLA combined to polypropylene leads to an absence of mesh shrinkage and lower inflamation, leading to better tolerance compared to 100% polypropylene meshes.

The in-vivo animal study also shows earlier and higher amount of collagen fibers, thus an earlier support for abdominal wall repair.

## Easy to place<sup>(2)</sup>

Specifically in laparoscopy, thanks to the hydrophilic attribute of PLLA that holds the mesh in place against the abdominal wall.

Monofilament polypropylene + resorbable PLLA



Monofilament polypropylene

### > A FULL PRODUCT RANGE

#### LICHTENSTEIN




#### TAPP / TEP







Pre-cut



Flap

### > MATERIAL

75% PLLA - resorbable / 25% polypropylene - non resorbable

(1) Tanaka K., Mutter D., Inoue H., Lindner V., Bouras G., Forgione A., Leroy J., Aprahamian M., Marescaux J. In Vivo evaluation of a new composite mesh 10% Polypropylene/90% Poly-L-Lactic Acid for Hernia Repair. J Mater Sci: Mater Med 2007; 18: 991-999. Animal study.

(2) Preliminary results from ongoing multicenter 4DMesh® clinical study - Club Hernie registry.

uire- 🧖

4DMesh is a class III medical device manufactured by COUSIN BIOTECH s.a.s. The management system of COUSIN BIOTECH s.a.s has been certified as meeting the requirements of ISO 13485. Please read instructions for use carefully. Reference: FPV4DMGB01 - 22/04/15

Non contractual pictures and texts. Specifications likely to be modified without notice.

Cousin Biotech S.A.S capital: 340 656 € - 398 460 261 RCS Lille - N°TVA FR 34 398 460 261